OssiaLabs Bone Health Formula
OSSTIVIA
BONE MODULATION
SUPPLEMENT
Osstivia is a liquid bone modulation supplement by OssiaLabs, built around Fructus Ligustri Lucidi (FLL) and SNEDDS nano-delivery to support bone metabolism and the body's response to mechanical stimulation.
3X
Concentrated Extract
6+
Pathway Targets
SNEDDS
Nano-Delivery System
PATHWAY NETWORK
Click nodes for mechanism detail
Filter
Ctrl + scroll to zoom Click nodes to explore
Delivery System
THE SNEDDS ADVANTAGE
Standard FLL extracts and powders struggle with first-pass hepatic metabolism. Osstivia's SNEDDS formulation bypasses this entirely, delivering active compounds directly into systemic circulation.
01
Nano-Emulsification
Upon GI contact, SNEDDS spontaneously forms lipid nano-droplets under 200 nm. Dramatically increases surface area for absorption.
02
P-gp Inhibition
SNEDDS surfactants inhibit P-glycoprotein efflux transporters, preventing active efflux of FLL compounds back into the gut lumen.
03
Lymphatic Bypass
Nano-droplets are packaged into chylomicrons absorbed via lymphatic lacteals, completely bypassing hepatic first-pass metabolism.
04
Systemic Saturation
Active compounds enter circulation at full potency, achieving significantly higher plasma concentrations than conventional oral delivery.
SNEDDS self-nanoemulsification mechanism: spontaneous formation of oil-in-water nano-droplets (<200 nm) upon GI contact, expanding intestinal absorption surface area far beyond a conventional capsule
SNEDDS advantages over conventional oral delivery: enhanced solubility, dissolution rate, mucosal permeation, P-gp efflux inhibition, and lymphatic transport for dramatically improved bioavailability
SNEDDS nano-droplet characterization: particle size distribution, zeta potential stability, and dissolution profile in simulated GI fluid demonstrating rapid self-emulsification
Ternary phase diagram for SNEDDS formulation optimization: oil/surfactant/co-surfactant ratios defining the self-emulsification region and nano-droplet formation boundary
Self-double-emulsifying nanoparticle structure: oil core and water phases stabilized by hydrophilic and lipophilic emulsifier shells — upon GI contact, SNEDDS spontaneously forms nano-droplets improving intestinal permeation of lipophilic FLL compounds
Free drug vs SNEDDS intestinal absorption comparison: conventional oral capsule disperses poorly above the mucosal barrier (low bioavailability) versus SNEDDS lipid nano-droplets that efficiently penetrate intestinal epithelium for significantly enhanced systemic absorption
Molecular Mechanisms
GROWTH MECHANISMS
FLL acts on multiple synergistic pathways simultaneously. By using SNEDDS, Osstivia saturates these critical nodes far more effectively than standard extractions or powders.
Important: Osstivia is both dose and time dependent. Consistent, sustained application is required to trigger and maintain the growth pathways documented below.
01 Bone Formation
Wnt/beta-catenin and BMP-Smad Signaling
FLL active compounds strongly upregulate Wnt and BMP-2 pathways. This triggers expression of RUNX2 and Osterix (Osx), the master transcription factors for osteoblast differentiation. In simple terms: it signals your body to increase production of new bone matrix.
Kong et al. Bioengineered. 2022;13:10640
Chen et al. Molecules. 2017;22:1469
02 Inhibiting Bone Breakdown
OPG/RANKL/RANK Axis
FLL significantly improves the OPG/RANKL ratio. By downregulating RANKL and upregulating Osteoprotegerin (OPG), it prevents activation of NF-kB and MAPK pathways, effectively suppressing osteoclastogenesis and halting excessive bone breakdown.
Xu et al. Mol Med Reports. 2016;14:4767
Tang et al. Chin Med. 2020;15:87
03 Cell Survival and Oxidative Protection
PI3K/Akt Pathway and Antioxidant Defense
FLL activates PI3K/Akt signaling, promoting osteoblast survival and proliferation. It also engages the Nrf2/HO-1 antioxidant axis to protect bone-forming cells from oxidative stress and apoptosis, ensuring cells remain healthy during heavy mechanical loading.
Li et al. Aging (Albany NY). 2019;11:9348
04 Mineralization Environment
Calcium Homeostasis (TRPV6/VDR)
FLL compounds modulate the parathyroid hormone (PTH) and Vitamin D receptor (VDR) networks. This upregulates TRPV6 to dramatically increase intestinal and cellular calcium absorption, ensuring raw materials for bone mineralization are available when the jaw is strained.
Chen et al. J Ethnopharmacol. 2021;279:114348
05 Natural Anabolic Support
Ursolic Acid, Oleanolic Acid, Salidroside
Osstivia contains compounds native to FLL, including Ursolic Acid, Oleanolic Acid, and Salidroside. These botanical components function as natural anabolics with promising evidence for supporting muscle health and function via IGF-1/PI3K/mTORC1 signaling.
Wal et al. Russ J Bioorg Chem. 2025;51:1
Feng et al. Front Immunol. 2025;16
Phytochemistry
ACTIVE COMPOUNDS
Fructus Ligustri Lucidi contains a rich array of bioactive triterpenes, iridoids, and phenylpropanoids. Osstivia standardizes these to HPLC-verified concentrations.
Oleanolic Acid
15-20% by HPLC
Hepatoprotective, inhibits PPARgamma to suppress BMSC adipogenesis in favor of osteoblastic differentiation. Activates Nrf2/ARE cytoprotection.
Ursolic Acid
Natural Triterpene
Activates BMP/Smad signaling in BMSCs, suppresses NF-kB and pro-inflammatory cytokines, reprograms macrophages from M1 to M2 phenotype.
Salidroside
Elite Adaptogen
Activates AMPK/Sirt1/PGC-1alpha for mitochondrial resilience, blocks Abeta aggregation, modulates HPA axis to reduce cortisol-mediated bone loss.
Oleuropein / Echinacoside
Iridoid Glycosides
Potent antioxidants and anti-inflammatory agents that complement the triterpene fraction. Echinacoside promotes osteoblast proliferation and ALP activity.
Nuzhenide
Secoiridoid Glycoside
Regulates gut microbiota diversity and increases SCFA production. Supports systemic calcium balance via PTH/VDR axis modulation.
Specnuezhenide
Secoiridoid Glycoside
Modulates SIRT6 expression, linked to NAD-dependent anti-aging pathways and NF-kB suppression in bone tissue.
Frontiers in Pharmacology 2024: FLL phytochemistry, pharmacology, and bioavailability overview diagram
Empirical Data
THE RESEARCH
Fructus Ligustri Lucidi is one of the most rigorously studied botanicals for bone metabolism. The data demonstrates clear modulation of both osteoblastic formation and osteoclastic resorption, alongside a newly identified Sirt6-dependent pathway directly linking FLL to NF-kB suppression and osteoclast inhibition.
GO:0071363
Cellular Response to Growth Factor Stimulus
GO enrichment analysis of FLL identifies "cellular response to growth factor stimulus" as one of the most significantly upregulated biological processes. This is mechanistically critical: FLL-treated bone cells are measurably more sensitive to IGF-1, TGF-β, and BMP-2 signals, amplifying the anabolic cascade in response to endogenous growth factor activity throughout the skeletal system.
NEW MECHANISM
FLL, Sirt6, NF-kB, Cathepsin K Axis
Recent research establishes a novel mechanistic cascade: FLL bioactives upregulate Sirt6 (a NAD-dependent deacetylase) in osteoblasts. Sirt6 then deacetylates and inactivates NF-kB p65, reducing transcription of Cathepsin K, the primary collagenase responsible for bone matrix degradation by osteoclasts. This Sirt6-mediated brake on osteoclastogenesis is independent of the classical RANKL/OPG pathway, giving FLL a dual-axis anti-resorption mechanism.
Suppresses RANKL-induced osteoclastogenesis via NFATc1 inhibition
Activates Wnt/beta-catenin via DKK1/SOST inhibition, osteoblast formation
Increased BMD in dose-dependent manner (high-dose: 0.32 g/cm2 vs control 0.26)
Significantly increased Ca absorption and retention rates (p less than 0.01)
Increased epiphyseal growth plate cartilage thickness by 24% to 32%
GO:0071363 enrichment: sensitizes cells to growth factor stimulus (IGF-1, TGF-beta)
FLL multi-pathway mechanism: three convergent axes — (1) PTH/CaSR/VDR calcium regulation, (2) ERα/RANKL/OPG/MAPK/Akt osteoclast suppression, (3) Nox4/ROS/NF-κB antioxidant control — inhibiting osteoclastogenesis and promoting osteoblastogenesis
FLL bioactive compound library: 14 pharmacologically active molecules — triterpenoids (oleanolic acid, ursolic acid), iridoid glycosides (nuzhenide through oleoside esters), phenylethanoid glycoside (salidroside), and phenols (hydroxytyrosol, tyrosol, tyrosyl acetate)
Morris water maze: FLL restores spatial memory and learning in aging mice — significantly more platform crossings, greater target zone dwell time, and reduced escape latency vs. aging controls (swim paths and bar charts, Normal/Aging/VE/FLL groups)
FLL articular cartilage protection: H&E (10×) and Safranin-O/glycosaminoglycan staining (10× & 20×) showing FLL preserves cartilage proteoglycan matrix in aging — IOD values quantified across Normal/Aging/VE/FLL groups
FLL suppresses NF-κB p65 acetylation and Cathepsin K in aging bone: IHC (20×/40×) and western blot showing FLL reduces Acetyl-NF-κB-p65 (Lys310) and Cathepsin K protein in osteoclast-rich bone tissue (Normal/Aging/Aging+FLL)
FLL 3D microCT and biomechanics: 3D bone reconstruction with dose-dependent improvements in trabecular parameters (BV/TV, Tb.N, Tb.Sp, Tb.Th) and cortical metrics (Ct.Ar, Ct.Th), plus whole-bone mechanical strength (ultimate load, bending strength, elastic modulus)
FLL upregulates Sirt6 in brain neurons and bone tissue: DAB immunostaining in hippocampal neurons (top panels) and osteoblasts (bottom panels), confirmed by western blot; FLL also restores serum IL-2 and reduces TNF-α in aging (Normal/Aging/Aging+FLL)
FLL dual mechanism pathway diagram: D-gal+NaNO2 induces gut flora dysbiosis → FMO3 → TMAO → oxidative stress; FLL blocks this via Sirt6 upregulation → NF-κB-p65 suppression → Cathepsin K reduction, protecting both bone (↓senile osteoporosis) and brain (↓cognitive deficit)
Ursolic acid (FLL triterpenoid) macrophage mechanism: inhibits LPS/TLR-4 → M1 macrophage activation, balances M1/M2 polarization, induces autophagy — systemic protection of brain (Alzheimer/depression/ischemia), bone (osteoporosis), blood vessels (atherosclerosis), liver, and skin
Ursolic acid immunological network: macrophage M1/M2 polarization balance (TNF-α/IL-6 → IL-10/TGF-β), LPS/TLR-4/NF-κB/pSTAT1/MAPK suppression, autophagy induction — mechanistic links to osteoporosis (osteoclast MAPK/JNK), Alzheimer/depression, liver fibrosis, atherosclerosis
Ursolic acid multi-organ body map: brain (Alzheimer/neuritis via ROS/NF-κB/NLRP3 in microglia), bone (osteoporosis via JNK/MAPK/TLR/NF-κB osteoclast differentiation), blood vessels (atherosclerosis via NOX4/NF-κB), liver (fibrosis via Kupffer/NLRP3 pyroptosis), skin (wound healing)
Ursolic acid five-organ radial effects: bone (inhibit osteoclast differentiation), skin (inflammation regulation, wound healing), blood vessels (autophagy promotion, foam cell restriction), brain (neuroinflammatory regulation, neuroprotection), liver (fibrosis regulation, immune surveillance)
Ursolic acid broad pharmacological profile: 11 documented bioactivities — antifungal, antimalarial, antihistaminic, cardioprotective, anti-inflammatory, anticancer, antioxidant, antidiabetic, antibacterial, antiproliferative, and chemopreventive
Ligustrum lucidum Fruit (LLF) comprehensive mechanism: four simultaneous actions — bone remodeling balance (inhibit osteoclastogenesis, promote osteoblast activity), calcium homeostasis (CaSR/PTH axis), Nox4/ROS/NF-κB antioxidant suppression, and BMSCs differentiation (inhibit adipogenesis, promote osteogenesis)
Ligustrum lucidum multi-system pharmacology: anti-inflammatory (NF-κB/MAPK/HO-1), anti-tumor (casp-3/8/9 apoptosis, PI3K/Akt/MMP2 migration), anti-osteoporosis (NFATc1/ERK osteoclasts + Wnt/β-cat/BMP osteoblasts), hepatoprotection (LXR-α/SREBP/Smad4), antioxidant (NOx4/SOD/GSH-Px), anti-depression (CaSR/TLR4/NLRP3)
FLL calcium homeostasis mechanism: kidney activation of 1,25(OH)₂D₃ → intestinal TRPV6/CaBP-9K/VDR transporter upregulation, plus gut microbiota short-chain fatty acids (SCFAs) → combined enhanced intestinal Ca²⁺ absorption → net bone calcium deposition
FLL Triterpene Structure: Oleanolic Acid Molecular Formula (C₃₀H₄₈O₃ — pentacyclic triterpenoid backbone shared with ursolic acid)
FLL iridoid glycoside structures: oleoside-type iridoid variants (compounds 1–5), including salidroside-type ester and phenylalanine ester variants — key bioactive glycoside scaffolds in Ligustrum lucidum Fruit
Oleanolic acid (FLL active compound): anti-osteoclast mechanism — suppresses RANKL-induced osteoclastogenesis, blocks TRAF6/NF-κB/c-Fos/NFATc1 cascade, and supports osteoblast differentiation via BMP/Smad pathway activation
Oleanolic acid pharmacological research: bone formation pathway activation, osteoblast differentiation support, and anti-resorptive properties documented — one of the primary active triterpenoids delivered by Osstivia SNEDDS formulation
FLL Research Library
RESEARCH SNIPPETS
Direct excerpts and figures from peer-reviewed studies on Fructus Ligustri Lucidi. Click any card to expand. Use arrows or dots to browse.
Human Evidence
CLINICAL TRIAL DATA
A clinical trial involving women taking FLL powder documented significant improvements in bone mineral density. This used a basic milk powder delivery method. With SNEDDS, results are expected to be substantially superior.
0.32 g/cm2
High-Dose Group BMD
vs. control 0.26 g/cm2. Statistically significant (p less than 0.05). Leung et al. 2015
Milk Powder
Delivery Method Used
Basic oral delivery with first-pass metabolism intact. Osstivia SNEDDS bypasses this entirely for greater efficacy.
p < 0.01
Calcium Retention Significance
Both Ca absorption rate and Ca retention rate significantly improved (Chen et al. 2021)
Leung et al. 2015 clinical conclusion: rich laboratory evidence and positive clinical observations establish FLL as a safe, effective nutritional supplement for bone health — recommended as a perfect choice for bone mineral density maintenance
Leung et al. 2015 clinical trial: >0.5% increase in both hip and spine BMD after 3 months of FLL supplementation — statistically significant vs. control group, zero adverse events, no body weight gain
Biochemical markers: calcium, phosphorus, and bone turnover markers across study groups
Clinical trial conclusion: FLL supplementation produces significant improvements in BMD even with basic milk powder delivery
SNEDDS Advantage vs. Milk Powder Delivery
| Property | Milk Powder (Trial) | Osstivia SNEDDS |
|---|---|---|
| Bioavailability | Low (first-pass loss) | High (lymphatic) |
| P-gp Efflux | Active efflux intact | Inhibited |
| Compound Integrity | Degraded in gut | Protected |
| Expected Efficacy | Baseline (proven) | Significantly superior |
Mandibular Remodeling
THE MECHANISM
Bone tissue retains active remodeling potential throughout adulthood. Osstivia modulates multiple independent biochemical pathways that govern both bone formation and resorption simultaneously.
1
Osstivia Amplifies Growth Factor Sensitivity
FLL-treated cells are measurably more sensitive to IGF-1, TGF-β, and BMP-2 signals (GO:0071363 enrichment — one of the top FLL-enriched biological processes). Bone-forming cells respond more strongly to the growth factor environment present throughout the body, amplifying the anabolic cascade.
2
BMP/Smad Drives Hypertrophic Zone Expansion
Amplified BMP-2 signaling activates RUNX2 and Osterix in chondrocytes, driving differentiation into hypertrophic chondrocytes. FLL increases hypertrophic zone thickness by 24% to 32% in vivo, directly expanding the active growth front of bone tissue.
3
Endochondral Ossification Converts Cartilage to Bone
Hypertrophic chondrocytes mineralize their matrix. Vascular invasion follows. Osteoblasts colonize and deposit new bone. ALP cleaves pyrophosphate to enable hydroxyapatite crystal formation. Wnt/β-catenin maintains osteoblast commitment throughout the process.
4
OPG/RANKL Balance Protects New Bone
Simultaneously, FLL suppresses RANKL expression and upregulates OPG, preventing osteoclast activation and protecting newly deposited bone matrix from premature resorption. c-Fos/AP-1 and TRAF6/NF-kB suppression ensure the resorptive cascade stays suppressed throughout the remodeling cycle.
Peer-Reviewed Evidence: Adult Condylar Growth Potential
Lubsen et al. (1987) demonstrated that mandibular condyles in the third decade of life show hypertrophic growth cartilage with active endochondral ossification, with persistence documented into the early fourth decade in males. Kapoor et al. (Seminars in Orthodontics 2025) confirms biomolecular signals for condylar growth including PTHrP/Ihh/Sox9 axis, BMP-2, and Wnt signaling.
Lubsen et al. 1987: Third/fourth decade condylar ossification
Kapoor et al. Semin Orthod. 2025
Whole-Body Benefits
BEYOND BONE
While Osstivia is engineered for bone modulation, the highly concentrated FLL extract offers a massive spectrum of whole-body health benefits heavily documented in scientific literature.
Gut Support
Anti-Aging
Antioxidant
Calcium Regulation
Immune Modulation
Liver Support
Adaptogenic
Neuroprotective
GUT SUPPORT
Gut Microbiota and Digestion
FLL positively regulates gut microbiota diversity and significantly increases production of beneficial short-chain fatty acids (SCFAs). Also promotes calcium balance simultaneously (Chen et al. J Ethnopharmacol. 2021;279:114348).
ANTI-AGING, ANTIOXIDANT
Antioxidant and Anti-Aging Defense
Engages Nrf2/HO-1 antioxidant pathways. Modulates Sirt6 and TMAO levels, proteins strongly linked to longevity and protection against cellular aging (Li et al. Aging. 2019;11:9348).
CALCIUM REGULATION
Systemic Calcium Balance
Studies show significant increases in both Ca absorption rate and Ca retention rate (p less than 0.01) via PTH/VDR/TRPV6 upregulation, ensuring the system has raw building blocks for sustained mineralization.
IMMUNE MODULATION, Ursolic Acid
Macrophage and Immune Regulation
Ursolic Acid suppresses pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6) via NF-kB/AP-1/STAT3 inhibition and reprograms macrophages from M1 to M2 phenotype (Feng et al. Front Immunol. 2025).
LIVER SUPPORT, METABOLIC, Oleanolic Acid
Hepatoprotective and Metabolic Health
Verified by HPLC to contain 15-20% Oleanolic Acid. Acts as a profound liver protectant, reduces ALT/AST, activates Nrf2/ARE cytoprotection, aids metabolic conditioning and lipid metabolism regulation.
NEUROPROTECTIVE, ADAPTOGENIC, Salidroside
Neuroprotection and Adaptogenic Shield
Salidroside activates AMPK/Sirt1/PGC-1alpha for mitochondrial resilience, blocks Abeta aggregation, modulates HPA axis to reduce cortisol-mediated bone loss, and supports cognitive vitality.
Protocol Guide
CARE AND USAGE
Osstivia is an advanced liquid formulation. How you take it, store it, and pair it matters. Follow this guide to get the most out of your protocol.
How to Take It
Take Osstivia orally via the glass dropper that comes with the bottle. The dropper is marked with precise measurements so you can easily track your daily mL dosage.
Do NOT
- x Refrigerate
- x Place near direct sunlight
- x Put in super warm liquids
- x Mix into oil
- x Shake if already diluted
You CAN
- v Take by itself or in water
- v Drink other beverages before/after
- v Shake the bottle before use (undiluted)
- v Pair with Vitamin D3, K2, and Calcium
Safety and Toxicology
Osstivia has had no negative side effects reported at all. Extensive studies show FLL is remarkably safe and lacks systemic toxicity even in high amounts.
Zero adverse events in clinical trial (Leung et al. 2015)
Taste Profile
This is an advanced formulated product. It does not taste sugary or artificial. Some users are sensitive to the excipients, while others don't mind. It is an acquired taste you will get used to.
Consistency Is Key
Because Osstivia is dose and time-dependent, we highly recommend a pack of 5-6 bottles (60 mL) to maintain a consistent 1-2 mL daily protocol. The pathways targeted by FLL require sustained activation, not sporadic dosing, to produce measurable structural change.
GET OSSTIVIAOsstivia FAQ
OSSTIVIA BONE MODULATION SUPPLEMENT FAQ
Clear answers for people comparing Osstivia with conventional bone modulation supplements, mineral formulas, and botanical bone health protocols.
What is Osstivia?
Osstivia is a liquid bone modulation supplement from OssiaLabs built around Fructus Ligustri Lucidi (FLL) and SNEDDS nano-delivery.
Is Osstivia a bone modulation supplement?
Yes. Osstivia is positioned as a bone modulation supplement focused on FLL bioactives, bone metabolism pathways, and support for the body's response to mechanical stimulation.
What makes it different?
Many bone modulation supplements focus on minerals alone. Osstivia combines FLL botanical compounds with SNEDDS delivery technology designed to improve oral delivery of lipophilic bioactives.
How does SNEDDS improve bioavailability?
SNEDDS (Self Nano-Emulsifying Drug Delivery System) spontaneously forms lipid nano-droplets under 200 nm upon GI contact, bypassing first-pass hepatic metabolism via lymphatic absorption and inhibiting P-glycoprotein efflux.
What is the recommended protocol?
Take 1–2 mL daily via the glass dropper, consistently. Osstivia is dose- and time-dependent — sustained application is required to trigger and maintain the growth pathways documented in the literature.
Is it safe?
Yes. FLL has been used in traditional medicine for centuries and is backed by modern clinical data. Leung et al. (2015) reported zero adverse events in a 3-month human clinical trial. Osstivia has had no negative side effects reported at all.
How long until I see results?
Bone modulation is a gradual biological process. The clinical trial observed significant BMD improvements after 3 months of consistent supplementation. Structural change requires sustained activation of the relevant pathways — plan for a multi-bottle protocol.
What does it taste like?
Osstivia is an advanced formulated product — not sugary or artificial. Some users are sensitive to the excipients, while others don't mind. It is an acquired taste you will get used to.
Can I pair it with other supplements?
Yes. Osstivia pairs well with Vitamin D3, K2, and Calcium — nutrients that work synergistically with the PTH/VDR and calcium absorption pathways FLL targets. Avoid refrigerating or diluting in warm liquids.